Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration

Cleveland Clinic Journal of Medicine

Volumn 71, Issue SUPPL. 3, 2004, Pages

  Patel, Keyur ^a   McHutchison, John G ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA;

DISEASE COURSE; DOSE RESPONSE; ERADICATION THERAPY; HEPATITIS C; HUMAN; LIVER FIBROSIS; OPTIMAL DRUG DOSE; PRESCRIPTION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ALGORITHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPATITIS C VIRUS; LIVER CIRRHOSIS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VIROLOGY;

ADMINISTRATION, ORAL; ALGORITHMS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; PATIENT COMPLIANCE; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 6044272647     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.suppl_3.s8     Document Type: Review

References (9)

1. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28:1121-1127.
2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 KD) in combination with ribavirin: efficacy and safety results from a phase III, randomized, double-blind, multicenter study examining the effect of duration of treatment and RBV dose. J Hepatol 2002; 36(suppl 1):3. Abstract.
7. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36(5 suppl 1):S145-S151.
8. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
9. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.